Work

Le deucravacitinib, inhibiteur sélectif de la tyrosine kinase 2 (TYK2) oral, comparé au placebo et à l’aprémilast dans le psoriasis en plaques modéré à sévère: efficacité selon le traitement antérieur dans les essais de phase 3 : POETYK PSO-1 et PSO-2

Year: 2021

Type: article

Source: Annales de Dermatologie et de Vénéréologie - FMC

DOI: 10.1016/j.fander.2021.09.424

Authors: Carle Paul, Richard B. Warren, April Armstrong, Shinichi Imafuku, Leon Kircik, Subhashis Banerjee, Elizabeth Colston, Tao Wang, John Throup, Bruce Strobe

Institutions: Université Toulouse III - Paul Sabatier, Hôpital Larrey, Salford Royal NHS Foundation Trust, University of Manchester, NIHR Manchester Biomedical Research Centre, University of Southern California, Fukuoka University Hospital, Icahn School of Medicine at Mount Sinai, Bristol-Myers Squibb (United States), Yale University

Language: French

Topic: Psoriasis: Treatment and Pathogenesis

Subfield: Immunology

Field: Immunology and Microbiology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W3214810089

FWCI:

Cites:

Cited by:

Related to: 10